-
Injection Immunotherapies Get FDA Approval
Giving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
-
Immunotherapy Drug Tarlatamab Approved for Advanced Small Cell Lung Cancer
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
by Laura Gesualdi-Gilmore
-
Vaccines Spark Activity in Pancreatic Cancer
Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.
by Thomas Celona
-
TIL Therapy Amplifies the Immune System’s Attack on Melanoma
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
by Sandra Gordon
-
Light at the End of the Tunnel for ASPS Patients
Immunotherapy has helped some young people with alveolar soft part sarcoma (ASPS), a rare cancer, but there’s more work to be done.
by Kyle Bagenstose
-
CAR T-cell Therapy: Understanding the Warning and the Risks
The FDA requires a warning with CAR T-cell therapies about an increased risk of cancer from the treatment. Should you be concerned?
by Sandra Gordon
-
Consider Immunotherapy Before Surgery for Melanoma
Immunotherapy before surgery is proving to be an effective treatment against melanoma.
by Sandra Gordon
-
A Treatment That Came Just in Time
Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.
by Laurie Adami
-
Expanding Immunotherapy
At a patient advocate event, researchers discussed how to extend the benefits of immunotherapy to more people.
by Kevin McLaughlin
-
How Long Do Immunotherapy Side Effects Last?
For people with melanoma who receive immune checkpoint inhibitors after surgery, side effects can remain even after treatment has been completed. These chronic side effects are most often mild.
by Anna Goshua
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore